5 Oversold NASDAQ Stocks to Buy

Page 5 of 5

1. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

14-day RSI as of July 28: 14.28

Number of Hedge Fund Holders: 42

Waltham, Massachusetts-based Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is a biopharmaceutical company focused on the development of therapies for treatment of debilitating diseases by controlling complement, part of the body’s immune system. The company is exploring programs across ophthalmology, nephrology, hematology, and neurology by targeting the C3, the only target in the complement cascade that addresses all three pathways that can drive disease.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) received FDA approval of SYFOVRE™ (pegcetacoplan injection) in February 2023 for the treatment of geographic atrophy. EMPAVELI, for the treatment of Paroxysmal Nocturnal Hemoglobinuria, is the other commercial product of the company.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) ranks #1 on our list of 10 oversold NASDAQ stocks to buy based on the 14-day RSI of 14.28. The shares of the company were also widely owned by hedge funds, as of Q1 2023, with 42 of the 934 prominent hedge funds tracked by Insider Monkey holding its shares valued at $2.0 billion.

You may also like to read 10 Most Oversold S&P 500 Stocks Right Now and 10 Best Small Cap AI Stocks To Buy Now

Page 5 of 5